The Blind Spot of the Horizontal-Division Era: Where Can Japan's Bio-CDMOs Actually Win?

Over the past two decades, the way medicines are made has quietly changed—from chemically synthesized small molecules to biologics manufactured inside cells and microbes. With that shift, the "horizontal division of labor" that separates drug discovery from manufacturing has become an industry norm, and the once-invisible role of contract development and manufacturing organizations (CDMOs) has stepped into the spotlight. The Japanese government, too, is placing this structural change at the center of national strategy. Yet the place where Japan has planted its flag and the place where it can actually win are not necessarily the same.

1. A National Tilt Toward "Manufacturing Power"

In its 2024 Bio Policy Action Plan, the Ministry of Economy, Trade and Industry (METI) named three priority areas: the drug-discovery venture ecosystem; vaccines and biologics; and regenerative/cell medicine and gene therapy. The common thread running through all three is the same—securing manufacturing capacity, i.e., CDMOs. The vision casts a division of labor in which ventures and academia concentrate on discovery while CDMOs handle production, and it sets the goal of securing that production capacity within Japan as a matter of national industrial structure.

Behind this lies a lesson from the pandemic. The experience of being unable to manufacture vaccines domestically elevated manufacturing power into a question of economic security. The measures are concrete: the program to strengthen vaccine production capacity by developing biologics manufacturing sites; capital-investment support for regenerative, cell, and gene-therapy manufacturing under the FY2024 supplementary budget (with awards announced in 2025); and a published list of domestic CDMOs compiled with the cooperation of the Forum for Innovative Regenerative Medicine. Boost scale through facilities, and make players visible through the list—Japan is cultivating its domestic manufacturing base from both the "capital" and "information" sides.

2. World-Class Players "Exist"—But Not Manufacturing in Japan

So does Japan have international competitiveness? The answer is sharply bifurcated. On the global front line, there is essentially one company: Fujifilm. It holds a top-three position in biologics CDMO worldwide, has invested a cumulative total of more than ¥1 trillion, and is set to reach world-class capacity of 660,000 liters by 2026. Eyeing ¥700 billion in sales by FY2030, it internally styles itself as "the TSMC of biopharmaceuticals." This is, without question, the real thing.

But that large-scale capacity sits in Denmark, the United States, and the United Kingdom—not at domestic sites in Japan. Even rival Samsung Biologics points out that Japanese CDMOs' large-scale commercial production is concentrated in North America and Europe, and that this is a challenge for Japanese pharmaceutical companies seeking a large-scale partner at home. "Japanese firms are world-class, but they aren't manufacturing in Japan"—this contortion is the single greatest gap between national policy and reality. Winning globally and securing manufacturing power at home are not the same thing.

3. Domestically Small, and Not Even "Free"

The two domestic giants, Fujifilm and AGC, are both large photo- and materials-conglomerates rather than pure-play independents. A category of independent CDMOs with real scale barely exists in Japan. The remaining players converge into three types.

First, the subsidiary-of-a-large-group type. Takara Bio (part of the Takara group), which bills itself as a leading company in cell and gene therapy, and Teijin Regenet, which entered via the J-TEC acquisition, belong here. Second, the specialized startup type. ARCALIS—a joint venture between Axcelead and Arcturus that focuses on mRNA and has built a base in Minamisoma, Fukushima—is the emblematic case. Third, the node-in-a-foreign-network type. As with Nikon partnering with Lonza or Teijin partnering with the U.S. firm Resilience, the choice to plug into a foreign network rather than build an independent brand is conspicuous.

Two structural weaknesses show through here. One is the high degree of linkage to a parent's pipeline. ARCALIS doubles as a manufacturing site for Arcturus, and Takara Bio is contiguous with its own gene-therapy development. This is different in character from the Samsung or Lonza model of neutrally taking on customers from around the world. The other is modality bias. The independents' main battleground skews toward the newer modalities—cell, gene, and mRNA—and their scale remains at the clinical-supply to early-commercial level. Taken together, their low international visibility is not merely an impression but an inevitability rooted in scale and this structure.

4. So Where Does the Opportunity Lie?

This is not a story that ends in pessimism. On the contrary, the opportunity lies on the flip side of the blind spot.

First, the very void of a "neutral, large-scale, pure-play" domestic option is itself an opportunity. The problem that Japanese pharmaceutical companies lack a domestic partner they can confidently entrust with high-volume manufacturing is, conversely, unmet demand. For new entrants—and for those positioned to consolidate the existing independents—this space is open. Second, the greenfield nature of the new modalities. Catching up to incumbents in antibody CDMO is extraordinarily hard, but in cell, gene, and mRNA, no commercial champion has yet been crowned worldwide. It is precisely in fields close to a level starting line that Japan can convert the depth of its research base—iPS cells foremost among them—into manufacturing competitiveness. Third, the tailwind of policy and dual use. Facility subsidies, the economic-security framing, and the concept of dual-use sites that can switch production to vaccines in an emergency are among the few levers that bolster the economics of locating in Japan.

In the end, the question facing Japan's bio-CDMOs is not "Can it build the world's number-one antibody plant?" That seat, embodied by Fujifilm, is already being secured offshore. The real question is who will fill the two voids—new modalities and neutral domestic capacity—using the tailwinds of research strength and policy. The weakness and the opportunity sit in the very same place.